Program
vepugratinib
Also written as “Vepugratinib”, “LY3866288” and “[14C]-LY3866288”.
Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Transitional Cell, led by Eli Lilly.
Furthest: phase 3, since Oct 9, 20255 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 53 open or running | phase 3since Oct 9, 2025 | Nov 7, 2022 | Jun 2027phase 1 · NCT05614739 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2022First study: phase 1 study in Urinary Bladder NeoplasmsFirst studyNCT05614739 · 677 planned · United States, Australia, Canada and more
- Oct 11, 20242 phase 1 studies in HealthyNCT06641037, NCT06644378
- Oct 9, 2025Phase 3 study in Carcinoma, Transitional CellNCT07218380 · 450 planned · United States, Australia, Brazil and more
- Sep 15, 2026Phase 2 study in Urinary Bladder NeoplasmsNCT07827612 · 161 planned · United States
Ahead
- Jun 2027Primary completion: phase 1 study in Urinary Bladder NeoplasmsNCT05614739
- Jul 2028Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT07827612
- Oct 2029Primary completion: phase 3 study in Carcinoma, Transitional CellNCT07218380
TargetBeta
FGFR3 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 3 (FGFR3), ”NCIt, by rule
Other programs on FGFR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| masitinibrule | AB Science | phase 3 | 38 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| dabogratinibrule | tyra-biosciences-inc | phase 2 | 5 |
| FGFR3/4 Inhibitor TYRA-430rule | tyra-biosciences-inc | phase 1 | 1 |
| Anti-FGFR3 Antibody-drug Conjugate BHV-1530rule | biohaven-therapeutics-ltd | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07827612Urinary Bladder Neoplasms · United States | 2 | Not yet recruiting | Jul 2028 | 161 |
| NCT07218380Carcinoma, Transitional Cell · United States, Australia, Brazil and more | 3 | Recruiting | Oct 2029 | 450 |
| NCT06644378Healthy · United States | 1 | Completed | Jan 3, 2025 | 15 |
| NCT06641037Healthy · United States | 1 | Completed | Dec 2, 2024 | 15 |
| NCT05614739Urinary Bladder Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Jun 2027 | 677 |
How it is read
Names in the registry
- “Vepugratinib”, 3 entries
- “LY3866288”, 2 entries
- “[14C]-LY3866288”, 2 entries
Conditions, from the studies’ own filings
- Urinary Bladder Neoplasms, 2 studies
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.